RIGEL PHARMACEUTICALS, INC. (RIGL) Debt Components
- 2026-06-30: Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m).
- 2026-06-30: Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m).
- 2026-03-31: Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m).
- 2026-03-31: Long-term DebtUSD $45.00M; Long-Term Debt, Maturity, Year OneUSD $22.50M; Long-Term Debt, Maturity, Year TwoUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m).
RIGEL PHARMACEUTICALS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Line of Credit Facility, Increase, Accrued Interest USD | Long-term Debt, Gross USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | (m) | (m) | 6 month · $100.00K | (m) | (m) | (m) | (m) |
| 2026-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | $40.00M | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | (m) | (m) | (m) | 3 month · $2.60M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $45.00M | $22.50M | (m) | (m) | $22.50M | (m) | $45.00M | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | 12 month · $2.60M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $52.50M | (m) | (m) | (m) |
| 2025-12-31 | $52.50M | $30.00M | $22.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $60.00M | $30.00M | $22.50M | (m) | $7.50M | (m) | $60.00M | (m) | (m) | (m) |
| 2025-06-30 | $60.00M | $30.00M | $22.50M | (m) | $7.50M | (m) | $60.00M | (m) | (m) | (m) |
| 2025-03-31 | $60.00M | $30.00M | $22.50M | (m) | $7.50M | (m) | $60.00M | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | 12 month · $2.10M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $60.00M | (m) | (m) | (m) |
| 2024-12-31 | $60.00M | $7.50M | $30.00M | $22.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $60.00M | $7.50M | $30.00M | $22.50M | (m) | (m) | $60.00M | (m) | (m) | (m) |
| 2024-06-30 | $60.00M | $7.50M | $30.00M | $22.50M | (m) | (m) | $60.00M | (m) | (m) | (m) |
| 2024-03-31 | $60.00M | $30.00M | $22.50M | (m) | $7.50M | (m) | $60.00M | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | 12 month · $1.50M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $60.00M | (m) | (m) | (m) |
| 2023-12-31 | $60.00M | (m) | $7.50M | $30.00M | (m) | (m) | (m) | $22.50M | (m) | (m) |
| 2023-09-30 | $60.00M | $7.50M | $30.00M | $22.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $60.00M | $7.50M | $30.00M | $22.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $60.00M | $7.50M | $30.00M | $22.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | 12 month · $800.00K | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $40.00M | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $600.00K |
| 2022-12-31 | $40.00M | (m) | $5.00M | $20.00M | (m) | (m) | (m) | $15.00M | (m) | (m) |
| 2022-09-30 | $40.00M | (m) | $5.00M | $20.00M | (m) | (m) | (m) | $15.00M | (m) | (m) |
| 2022-06-30 | $30.00M | $7.50M | $22.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $30.00M | $15.00M | $11.25M | (m) | $3.75M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $100.00K |
| 2021-12-31 | $20.00M | $2.50M | $10.00M | $7.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $20.00M | $2.50M | $10.00M | $7.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $20.00M | $2.50M | $10.00M | $7.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $20.00M | (m) | $6.67M | $6.67M | $1.67M | (m) | (m) | $5.00M | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $185.00K |
| 2020-12-31 | $20.00M | (m) | $1.67M | $6.67M | (m) | (m) | (m) | $6.67M | $5.00M | (m) |
| 2020-09-30 | $20.00M | (m) | $1.67M | $6.67M | (m) | (m) | (m) | $6.67M | $5.00M | (m) |
| 2020-06-30 | $20.00M | (m) | $1.11M | $6.67M | (m) | (m) | (m) | $6.67M | $5.55M | (m) |
| 2020-03-31 | $10.00M | (m) | $556.00K | $3.33M | (m) | (m) | (m) | $3.33M | $2.78M | (m) |
| 2019-12-31 | $10.00M | (m) | $556.00K | $3.33M | (m) | (m) | (m) | $3.33M | $2.78M | (m) |
| 2019-09-30 | $10.00M | (m) | $556.00K | $3.33M | (m) | (m) | (m) | $3.33M | $2.78M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |